Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model

Atsuko Katsumoto, Aline S. Miranda, Oleg Butovsky, Antônio L. Teixeira, Richard M. Ransohoff, Bruce Lamb

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Traumatic brain injury (TBI) is a critical public health and socio-economic problem worldwide. A growing body of evidence supports the involvement of inflammatory events in TBI. It has been reported that resident microglia and infiltrating monocytes promote an inflammatory reaction that leads to neuronal death and eventually behavioral and cognitive impairment. Currently, there is no effective treatment for TBI and the development of new therapeutic strategies is a scientific goal of highest priority. Laquinimod, an orally administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis, might be a promising neuroprotective therapy for TBI. Herein, we aim to investigate the hypothesis that laquinimod will reduce the central nervous system (CNS) damage caused by TBI. Methods: To test our hypothesis, Ccr2 rfp/+ Cx3cr1 gfp/+ mice were submitted to a moderate TBI induced by fluid percussion. Sham controls were submitted only to craniotomy. Mice were treated daily by oral gavage with laquinimod (25 mg/kg) 7 days before and 3 days after TBI. The brains of mice treated or not treated with laquinimod were collected at 3 and 120 days post injury, and brain morphological changes, axonal injury, and neurogenesis were evaluated by microscopy analysis. We also isolated microglia from infiltrating monocytes, and the expression of immune gene mRNAs were analyzed by employing a quantitative NanoString nCounter technique. Results: Laquinimod prevented ventricle enlargement caused by TBI in the long term. Immunohistochemical analyses revealed decreased axonal damage and restored neurogenesis in the laquinimod-treated TBI group at early stage (3 days post injury). Notably, laquinimod inhibited the monocytes infiltration to the brain. Hierarchial clustering demonstrated that the microglial gene expression from the TBI group treated with laquinimod resembles the sham group more than the TBI-water control group. Conclusions: Administration of laquinimod reduced lesion volume and axonal damage and restored neurogenesis after TBI. Laquinimod might be a potential therapy strategy to improve TBI long-term prognosis.

Original languageEnglish (US)
Article number26
JournalJournal of Neuroinflammation
Volume15
Issue number1
DOIs
StatePublished - Jan 30 2018

Fingerprint

Macrophages
Inflammation
Neurogenesis
Monocytes
Microglia
Traumatic Brain Injury
laquinimod
Percussion
Gene Expression
Craniotomy
Wounds and Injuries
Brain
Brain Injuries
Multiple Sclerosis
Cluster Analysis
Microscopy
Therapeutics
Central Nervous System
Public Health
Economics

Keywords

  • Laquinimod
  • Microglia
  • Peripherally derived monocytes
  • Traumatic brain injury

ASJC Scopus subject areas

  • Neuroscience(all)
  • Immunology
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model. / Katsumoto, Atsuko; Miranda, Aline S.; Butovsky, Oleg; Teixeira, Antônio L.; Ransohoff, Richard M.; Lamb, Bruce.

In: Journal of Neuroinflammation, Vol. 15, No. 1, 26, 30.01.2018.

Research output: Contribution to journalArticle

Katsumoto, Atsuko ; Miranda, Aline S. ; Butovsky, Oleg ; Teixeira, Antônio L. ; Ransohoff, Richard M. ; Lamb, Bruce. / Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model. In: Journal of Neuroinflammation. 2018 ; Vol. 15, No. 1.
@article{1338679647344a62ab64d62fa9686e86,
title = "Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model",
abstract = "Background: Traumatic brain injury (TBI) is a critical public health and socio-economic problem worldwide. A growing body of evidence supports the involvement of inflammatory events in TBI. It has been reported that resident microglia and infiltrating monocytes promote an inflammatory reaction that leads to neuronal death and eventually behavioral and cognitive impairment. Currently, there is no effective treatment for TBI and the development of new therapeutic strategies is a scientific goal of highest priority. Laquinimod, an orally administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis, might be a promising neuroprotective therapy for TBI. Herein, we aim to investigate the hypothesis that laquinimod will reduce the central nervous system (CNS) damage caused by TBI. Methods: To test our hypothesis, Ccr2 rfp/+ Cx3cr1 gfp/+ mice were submitted to a moderate TBI induced by fluid percussion. Sham controls were submitted only to craniotomy. Mice were treated daily by oral gavage with laquinimod (25 mg/kg) 7 days before and 3 days after TBI. The brains of mice treated or not treated with laquinimod were collected at 3 and 120 days post injury, and brain morphological changes, axonal injury, and neurogenesis were evaluated by microscopy analysis. We also isolated microglia from infiltrating monocytes, and the expression of immune gene mRNAs were analyzed by employing a quantitative NanoString nCounter technique. Results: Laquinimod prevented ventricle enlargement caused by TBI in the long term. Immunohistochemical analyses revealed decreased axonal damage and restored neurogenesis in the laquinimod-treated TBI group at early stage (3 days post injury). Notably, laquinimod inhibited the monocytes infiltration to the brain. Hierarchial clustering demonstrated that the microglial gene expression from the TBI group treated with laquinimod resembles the sham group more than the TBI-water control group. Conclusions: Administration of laquinimod reduced lesion volume and axonal damage and restored neurogenesis after TBI. Laquinimod might be a potential therapy strategy to improve TBI long-term prognosis.",
keywords = "Laquinimod, Microglia, Peripherally derived monocytes, Traumatic brain injury",
author = "Atsuko Katsumoto and Miranda, {Aline S.} and Oleg Butovsky and Teixeira, {Ant{\^o}nio L.} and Ransohoff, {Richard M.} and Bruce Lamb",
year = "2018",
month = "1",
day = "30",
doi = "10.1186/s12974-018-1075-y",
language = "English (US)",
volume = "15",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model

AU - Katsumoto, Atsuko

AU - Miranda, Aline S.

AU - Butovsky, Oleg

AU - Teixeira, Antônio L.

AU - Ransohoff, Richard M.

AU - Lamb, Bruce

PY - 2018/1/30

Y1 - 2018/1/30

N2 - Background: Traumatic brain injury (TBI) is a critical public health and socio-economic problem worldwide. A growing body of evidence supports the involvement of inflammatory events in TBI. It has been reported that resident microglia and infiltrating monocytes promote an inflammatory reaction that leads to neuronal death and eventually behavioral and cognitive impairment. Currently, there is no effective treatment for TBI and the development of new therapeutic strategies is a scientific goal of highest priority. Laquinimod, an orally administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis, might be a promising neuroprotective therapy for TBI. Herein, we aim to investigate the hypothesis that laquinimod will reduce the central nervous system (CNS) damage caused by TBI. Methods: To test our hypothesis, Ccr2 rfp/+ Cx3cr1 gfp/+ mice were submitted to a moderate TBI induced by fluid percussion. Sham controls were submitted only to craniotomy. Mice were treated daily by oral gavage with laquinimod (25 mg/kg) 7 days before and 3 days after TBI. The brains of mice treated or not treated with laquinimod were collected at 3 and 120 days post injury, and brain morphological changes, axonal injury, and neurogenesis were evaluated by microscopy analysis. We also isolated microglia from infiltrating monocytes, and the expression of immune gene mRNAs were analyzed by employing a quantitative NanoString nCounter technique. Results: Laquinimod prevented ventricle enlargement caused by TBI in the long term. Immunohistochemical analyses revealed decreased axonal damage and restored neurogenesis in the laquinimod-treated TBI group at early stage (3 days post injury). Notably, laquinimod inhibited the monocytes infiltration to the brain. Hierarchial clustering demonstrated that the microglial gene expression from the TBI group treated with laquinimod resembles the sham group more than the TBI-water control group. Conclusions: Administration of laquinimod reduced lesion volume and axonal damage and restored neurogenesis after TBI. Laquinimod might be a potential therapy strategy to improve TBI long-term prognosis.

AB - Background: Traumatic brain injury (TBI) is a critical public health and socio-economic problem worldwide. A growing body of evidence supports the involvement of inflammatory events in TBI. It has been reported that resident microglia and infiltrating monocytes promote an inflammatory reaction that leads to neuronal death and eventually behavioral and cognitive impairment. Currently, there is no effective treatment for TBI and the development of new therapeutic strategies is a scientific goal of highest priority. Laquinimod, an orally administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis, might be a promising neuroprotective therapy for TBI. Herein, we aim to investigate the hypothesis that laquinimod will reduce the central nervous system (CNS) damage caused by TBI. Methods: To test our hypothesis, Ccr2 rfp/+ Cx3cr1 gfp/+ mice were submitted to a moderate TBI induced by fluid percussion. Sham controls were submitted only to craniotomy. Mice were treated daily by oral gavage with laquinimod (25 mg/kg) 7 days before and 3 days after TBI. The brains of mice treated or not treated with laquinimod were collected at 3 and 120 days post injury, and brain morphological changes, axonal injury, and neurogenesis were evaluated by microscopy analysis. We also isolated microglia from infiltrating monocytes, and the expression of immune gene mRNAs were analyzed by employing a quantitative NanoString nCounter technique. Results: Laquinimod prevented ventricle enlargement caused by TBI in the long term. Immunohistochemical analyses revealed decreased axonal damage and restored neurogenesis in the laquinimod-treated TBI group at early stage (3 days post injury). Notably, laquinimod inhibited the monocytes infiltration to the brain. Hierarchial clustering demonstrated that the microglial gene expression from the TBI group treated with laquinimod resembles the sham group more than the TBI-water control group. Conclusions: Administration of laquinimod reduced lesion volume and axonal damage and restored neurogenesis after TBI. Laquinimod might be a potential therapy strategy to improve TBI long-term prognosis.

KW - Laquinimod

KW - Microglia

KW - Peripherally derived monocytes

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85041353136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041353136&partnerID=8YFLogxK

U2 - 10.1186/s12974-018-1075-y

DO - 10.1186/s12974-018-1075-y

M3 - Article

C2 - 29382353

AN - SCOPUS:85041353136

VL - 15

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 26

ER -